Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $38.57 Average Target Price from Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $38.57.

A number of equities analysts have recently commented on ZNTL shares. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of Zentalis Pharmaceuticals in a report on Wednesday, February 28th. Wedbush raised their price target on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, February 28th.

Insider Transactions at Zentalis Pharmaceuticals

In other news, CFO Melissa B. Epperly sold 2,573 shares of Zentalis Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the transaction, the chief financial officer now owns 451,449 shares in the company, valued at $5,164,576.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Matrix Capital Management Company LP increased its holdings in Zentalis Pharmaceuticals by 51.7% during the 2nd quarter. Matrix Capital Management Company LP now owns 13,959,973 shares of the company’s stock valued at $393,811,000 after purchasing an additional 4,760,000 shares during the period. Eventide Asset Management LLC increased its holdings in Zentalis Pharmaceuticals by 47.9% during the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after purchasing an additional 3,745,936 shares during the period. Decheng Capital LLC purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $31,809,000. Cormorant Asset Management LP purchased a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $30,890,000. Finally, State Street Corp increased its holdings in Zentalis Pharmaceuticals by 50.0% during the 2nd quarter. State Street Corp now owns 3,119,734 shares of the company’s stock valued at $87,665,000 after purchasing an additional 1,039,294 shares during the period.

Zentalis Pharmaceuticals Trading Up 3.8 %

Shares of ZNTL opened at $14.09 on Friday. The company has a market capitalization of $999.83 million, a price-to-earnings ratio of -3.10 and a beta of 1.72. The stock has a 50 day moving average of $13.37 and a 200 day moving average of $14.98. Zentalis Pharmaceuticals has a 12 month low of $9.56 and a 12 month high of $31.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.09. As a group, equities research analysts predict that Zentalis Pharmaceuticals will post -3.72 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.